PALI company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websitePalisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- J. D. Finley
- Listed since
- Mar 30, 2007
- Employees
- 14
Market position
Day range
Current $2.065
52-week range
Current $2.065
- Open
- $2.175
- Previous close
- $2.20
- Volume
- 1.9M
- 0.67× average
- Average volume
- 2.81M
- Average daily volume
- Market cap
- 358.44M USD
- Beta
- 1.55
- Market reference 1
- 50-day average
- $2.0332
- +1.56% above average
- 200-day average
- $1.9454
- +6.15% above average
